Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)

Condition: Asthma
Interventions: Drug: BHT 0.1%; Drug: BHT 0.5%; Drug: Placebo for RMT-B; Drug: Placebo for HFA-MDI
Sponsor: Boehringer Ingelheim
Completed – verified August 2014